Teligent, Inc. Announces FDA Approval of Ciclopirox Shampoo, 1%

BUENA, N.J., April 06, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Ciclopirox Shampoo, 1%. This is Teligent’s third approval for 2018, and its twenty-second approval from its internally-developed pipeline of topical generic pharmaceutical medicines.

Based on recent IQVIA data from January 2018, the total addressable market for this product is approximately $13.5 million.

“Ciclopirox Shampoo, 1% is Teligent’s third FDA approval in 2018,’’ commented Jason Grenfell-Gardner, President and CEO of the Company. “I am excited about Teligent’s continued growth and look forward to launching this product in the second quarter of 2018.”

Mr. Grenfell-Gardner continued, “We now have twenty-seven topical generic pharmaceutical products in the US portfolio, in addition to our four US injectable products.”

About Teligent, Inc.

Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.

Contact: 

Damian Finio
Teligent, Inc. 
856-336-9117
www.teligent.com